SCHEMBL13061135

SCHEMBL13061135

Cc1cccc(CN(CCN(C)C)Cc2ccccc2-c2ccccc2F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.44
CAMKK2 Q96RR4 1/20 0.44
CYP2D6 P10635 6/20 0.43
CYP1A2 P05177 5/20 0.43
CYP3A4 P08684 5/20 0.43
CYP2C19 P33261 3/20 0.43
KDM4E B2RXH2 4/20 0.41
MAPK1 P28482 2/20 0.41
LMNA P02545 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TSHR P16473 3/20 0.40
CYP2C9 P11712 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TAAR1 Q96RJ0 1/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 2/20 0.38
RECQL P46063 2/20 0.38
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
SLC1A5 Q15758 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005634 0.85 CALM1 (0.42) CALM1CAMKK2KDM4ELMNATSHR
SCHEMBL13060673 0.82 CALM1 (0.50) CALM1CAMKK2CYP2D6CYP1A2CYP3A4
SCHEMBL10039143 0.80 CALM1 (0.64) CALM1CAMKK2CYP2D6CYP2C19KDM4E
SCHEMBL13061100 0.78 CALM1 (0.55) CALM1CAMKK2KDM4ETSHRALDH1A1
SCHEMBL13005676 0.74 CALM1 (0.45) CALM1CAMKK2KDM4ETSHRSMN1; SMN2
SCHEMBL13060654 0.74 CALM1 (0.43) CALM1CAMKK2CYP2D6CYP1A2CYP3A4
SCHEMBL13061111 0.73 CALM1 (0.44) CALM1CAMKK2KDM4ETSHRSMN1; SMN2
SCHEMBL173006 0.72 CALM1 (0.43) CALM1CAMKK2CYP3A4KDM4ETSHR
SCHEMBL13061083 0.72 CALM1 (0.49) CALM1CAMKK2KDM4EHSD17B10TSHR
SCHEMBL13061029 0.72 MEN1 (0.49) CALM1CAMKK2CYP2D6CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed